Pulmonary Hypertension
Conditions
Brief summary
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance \[PVR\] and pulmonary blood volume \[PBV\]) of frespaciguat in participants with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The primary hypothesis is that 28 days of frespaciguat treatment is superior to placebo treatment in reduction of PVR.
Detailed description
Part 1 of this study will assess safety, tolerability, and PK of frespaciguat compared to placebo. Part 2 will assess safety, tolerability, PK, and changes in PVR and PBV of frespaciguat compared to placebo.
Interventions
DRUGFrespaciguat
Frespaciguat 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
DRUGPlacebo
Placebo administered as dry powder inhalation according to randomization
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Part 1 enrolled immediately. Part 2 enrolled following review of Part 1 pharmacokinetic data. A third part was planned but did not enroll because Part 2 yielded sufficient data and Part 3 was optional per protocol.
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Is male or female, from 40 to 80 years of age inclusive at the time of signing informed consent. * Be judged to have no untreated, clinically significant health issue from other comorbidities based on medical history, physical examination, vital signs and electrocardiograms performed at the screening visit(s) * Be judged to have no untreated, clinically significant health issue from other comorbidities based on laboratory safety tests performed at the screening visit(s) * Male participants are eligible to participate if they agree to the following during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) (eg, 5 terminal half-lives) plus an additional 90 days (a spermatogenesis cycle) after the last dose of study intervention. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or agrees to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: She is a woman of nonchildbearing potential (WONCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) * Have been diagnosed with mild to severe Chronic Obstructive Pulmonary Disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria (postbronchodilator forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio \< 0.7) * Has Modified Medical Research Council (MMRC) Dyspnea Score in the range of 1 through 3 at screening * Be deemed clinically stable by the investigator * Be or have suspected Pulmonary Hypertension Group 3 in particular: COPD * Have a history of right heart catheterization (RHC) within 3 years of starting study medication demonstrating mean pulmonary artery pressure (mPAP) ≥ 25mmHg and pulmonary vascular resistance (PVR) ≥ 3.75 Woods units or 300 dynes/sec/cm or have an echocardiogram performed by the investigator (or appropriate designee) at screening or within 1 year of screening demonstrating pulmonary artery systolic pressure ≥ 38 mmHg (Part 1 only) or ≥ 50 mmHg (Part 2 only) in conjunction with one or more of the following: tricuspid regurgitation velocity \>3 m/s or significant right heart enlargement and or reduced right heart function
Exclusion criteria
* Has pulmonary hypertension subtypes including the following according to Nice 2013 Clinical classification. This includes Group 1 Pulmonary arterial hypertension (PAH): Idiopathic PAH, Heritable PAH including Bone morphogenetic protein receptor type II (BMPR2), Activin A receptor type II-like kinase-1 (ALK1), endoglin, Sterile alpha motif domain-containing protein 9 (SMAD9), caveolin 1 (CAV1), potassium two-pore-domain channel subfamily K member 3 (KCNK3) and unknown, Drug and toxin-induced PAH, PAH associated with Connective tissue disease, HIV infection, Portal hypertension, Congenital heart disease (unrepaired and not requiring repair or repaired simple cardiac defects at least 1year status post corrective surgery, with no clinically significant residual shunt), Schistosomiasis, Chronic hemolytic anemia, Persistent pulmonary hypertension of the newborn (PPHN), and Pulmonary veno-occlusive disease (PVOD) and or pulmonary capillary hemangiomatosis (PCH); Group 2 Pulmonary hypertension owing to left heart diseases including Left ventricular Systolic dysfunction, Left ventricular Diastolic dysfunction, Valvular disease, Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies; Group 3 Pulmonary hypertension owing to lung diseases or hypoxia not associated with COPD including Interstitial lung disease, Other pulmonary diseases with mixed restrictive and obstructive pattern, Sleep-disordered breathing (mild obstructive sleep apnea (OSA) may be permitted with sponsor consultation), Alveolar hypoventilation disorders. Chronic exposure to high altitude, Developmental abnormalities; Group 4 Pulmonary hypertension defined as Chronic thromboembolic pulmonary hypertension \[CTEPH\]); and Group 5 Pulmonary Hypertension with unclear multifactorial mechanisms including Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, Splenectomy, Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleimyomatosis, neurofibromatosis, vasculitis, Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders, and Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension. * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic (not including chronic stable Hep B and C), immunological, renal, respiratory (not including PH-COPD), genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * Is mentally or legally incapacitated, has significant emotional problems at the time of pre-study (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator * Has a history of cancer (malignancy) except adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies which have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study, in the opinion of the investigator and with agreement of the Sponsor * Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or non-prescription drugs or food * Is positive for hepatitis B surface antigen (HBsAg) \[acute infection\] or HIV (participants with positive HBsAG that demonstrate low viral load (chronic stable infection) are permitted. * Part 2 only: Has known sensitivity to iodine or iodine containing products * Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit. * Has persistent or permanent atrial fibrillation with uncontrolled ventricular rate (participants with paroxysmal atrial fibrillation or controlled atrial fibrillation with no clinically significant arrhythmia may be allowed per the judgement of the investigator) * Has history of combined pulmonary fibrosis and emphysema (CPFE) or severe bullous emphysema. If no history, a confirmed negative high-resolution computerized tomography scan (HRCT) for these conditions needs to have been performed within last 2 ears. * Has an active respiratory infection (common cold, influenza, pneumonia, acute bronchitis) with lung function values (FEV1 and/or FEV1/FVC ratio) that do not meet eligibility range * Has a physical limitation that will inhibit the participant to effectively perform low intensity exercise testing (e.g. severe arthritis of the hip or knee) * Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit. There may be certain medications that are permitted * Is currently on monotherapy calcium channel blockers as a specific treatment for pulmonary hypertension * Is currently taking nitrates, inhaled prostacyclin, immediate or extended release diltiazem, phosphodiesterase 5 (PDE5) inhibitors or soluble guanylate cyclase (sGC) or activators for the treatment of pulmonary hypertension. Participants previously using medications to treat pulmonary arterial hypertension may be enrolled provided they have been off therapy for at least 2 weeks prior to the start of the screening period * Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit. The window will be derived from the date of the last visit in the previous study * Has FEV1 \< 30% predicted based on Pulmonary Function Tests (PFTs) at screening * Part 2 only: Does not meet RHC criteria at baseline * Participant has an estimated creatinine clearance of \< 60 mL/min based on the Cockcroft Gault equation at screening * Suffers from claustrophobia and is unable to undergo a computerized tomography (CT) scan * Has participated in a positron emission tomography (PET) research study or other research study involving administration of a radioactive substance or ionizing radiation within 12 months prior to the screening visit or has undergone or plans to have extensive radiological examination within the period with a radiation burden over 10 millisievert (mSv) * Does not agree to follow the smoking restrictions as defined by the clinical research unit (CRU) * Consumes greater than 3 glasses of alcoholic beverages * Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, energy drinks, or other caffeinated beverages per day * Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 12 months. Participants must have a negative urine drug screen (UDS) prior to randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) | Up to approximately 139 days | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was assessed. |
| Percentage of Participants Who Discontinued Study Drug Due to an AE | Up to approximately 32 days | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed. |
| Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2 | Baseline (between Day -5 and Day -1) and Day 28 | PVR was calculated in participants after MK-5475 dosing at baseline and Day 28. Based on the variables obtained by right heart catheterization (RHC), the fold change from baseline individual PVR was calculated. The difference from baseline was assessed on the log scale and then back-transformed for reporting (percent change from baseline). Per protocol, this outcome measure was only assessed during the Part 2 and was not assessed during part 1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1 | 24 hours postdose on Day 7 | Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Standard Deviation. Concentration values below the lower limit of quantification were treated as having a value of 0. |
| Time to Maximum Concentration (Tmax) of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475. |
| Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475. |
| Cmax Accumulation Ratio of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax. |
| AUC0-24 Accumulation Ratio of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken predose and at specified times postdose to determine the AUC0-24 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-24 to the Day 1 AUC0-24. |
| AUC0-inf Accumulation Ratio of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken predose and at specified times postdose on Days 1-7 to determine the AUC0-inf accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-inf to the Day 1 AUC0-inf. |
| AUC0-inf of MK-5475: Part 2 | Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken pre-dose and at specified times post-dose to determine the AUC0-inf of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. |
| Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken predose and at specified times postdose to determine the AUC0-inf of MK-5475. Plasma AUC0-inf was defined as the area under the concentration vs. time curve for MK-5475 from 0 to infinite hours. |
| Cmax of MK-5475: Part 2 | Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken predose and at specified times postdose to determine the Cmax of MK-5475. |
| Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 2 | 24 hours postdose on Day 7 | Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Coefficient of Variation, but due to data entry limitations the table below labels them as Geometric Mean and Geometric Coefficient of Variation. Concentration values below the lower limit of quantification were treated as having a value of 0. |
| Tmax of MK-5475: Part 2 | Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken predose and at specified times postdose to determine the Tmax of MK-5475. |
| t½ of MK-5475: Part 2 | Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken predose and at specified times postdose to determine the t½ of MK-5475. |
| AUC0-3 Accumulation Ratio of MK-5475: Part 2 | Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken predose and at specified times postdose on to determine the AUC0-3 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-3 to the Day 1 AUC0-3. |
| Cmax Accumulation Ratio of MK-5475: Part 2 | Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 15: 1 hour postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Cmax accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax. |
| Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2 | Baseline (between Day -5 and Day -1) and Day 28 | Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during part 1 and part 3. |
| AUC0-24 of MK-5475: Part 2 | Day 28: Predose, 0.5, 1, 2 and 3 hours postdose | Blood samples were taken predose and at specified times postdose on Day 28 to determine the AUC0-24 of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. AUC0-24 was calculated using extrapolated concentration at 24 hours postdose. |
| Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Blood samples were taken predose and at specified times postdose on Day 7 to determine the AUC0-24 of MK-5475. AUC0-24 values for Day 1 correspond to extrapolated values since collection on Day 1 stopped at 8 hours. |
| Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1 | Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose | Plasma concentration of MK-5475 was quantified for each arm to determine Cmax. |
Countries
Israel, Moldova, United States
Participant flow
Recruitment details
Adult participants with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) were recruited to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MK-5475.
Pre-assignment details
There were three planned parts in the study. Participants in part 1 received MK-5475 360 μg. Participants in part 2 received MK-5475 380 μg. Part 3 was not performed because, as allowed by the protocol, it was decided that sufficient data had already been obtained. One participant in Part 1 also participated in Part 2. That participant is counted only in Part 1 for the participant flow.
Participants by arm
| Arm | Count |
|---|---|
| Part 1: MK-5475 360 μg Participants received MK-5475 360 μg once daily (QD) via inhalation from Days 1-7. | 6 |
| Part 1: Placebo Participants received placebo QD via inhalation from Days 1-7. | 3 |
| Part 2: MK-5475 380 μg Participants received MK-5475 380 μg QD via inhalation from Days 1-28. | 8 |
| Part 2: Placebo Participants received placebo QD via inhalation from Days 1-28. | 5 |
| Total | 22 |
Baseline characteristics
| Characteristic | Part 2: Placebo | Total | Part 1: MK-5475 360 μg | Part 1: Placebo | Part 2: MK-5475 380 μg |
|---|---|---|---|---|---|
| Age, Continuous | 66.6 Years STANDARD_DEVIATION 5.6 | 65.8 Years STANDARD_DEVIATION 8.4 | 62.2 Years STANDARD_DEVIATION 12.7 | 62.3 Years STANDARD_DEVIATION 8.7 | 69.4 Years STANDARD_DEVIATION 4.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 22 Participants | 6 Participants | 3 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Pulmonary Vascular Resistance (PVR): Part 2 | 394.32 dynes*s*cm^-5 STANDARD_DEVIATION 141.18 | 404.46 dynes*s*cm^-5 STANDARD_DEVIATION 152.08 | — | — | 409.52 dynes*s*cm^-5 STANDARD_DEVIATION 166.47 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 22 Participants | 6 Participants | 3 Participants | 8 Participants |
| Sex: Female, Male Female | 0 Participants | 3 Participants | 1 Participants | 2 Participants | 0 Participants |
| Sex: Female, Male Male | 5 Participants | 19 Participants | 5 Participants | 1 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 3 | 0 / 9 | 0 / 5 |
| other Total, other adverse events | 2 / 6 | 1 / 3 | 2 / 9 | 4 / 5 |
| serious Total, serious adverse events | 0 / 6 | 0 / 3 | 1 / 9 | 1 / 5 |
Outcome results
Primary
Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2
PVR was calculated in participants after MK-5475 dosing at baseline and Day 28. Based on the variables obtained by right heart catheterization (RHC), the fold change from baseline individual PVR was calculated. The difference from baseline was assessed on the log scale and then back-transformed for reporting (percent change from baseline). Per protocol, this outcome measure was only assessed during the Part 2 and was not assessed during part 1.
Time frame: Baseline (between Day -5 and Day -1) and Day 28
Population: All Part 2 participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available data at baseline and Day 28.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2 | -21.23 Percentage change | Standard Deviation 16.98 |
| Part 1: Placebo | Percentage Change From Baseline to Day 28 in Pulmonary Vascular Resistance (PVR): Part 2 | -5.39 Percentage change | Standard Deviation 49.21 |
Primary
Percentage of Participants Who Discontinued Study Drug Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed.
Time frame: Up to approximately 32 days
Population: All participants who received ≥1 dose of investigational treatment were analyzed according to treatment received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: MK-5475 360 μg | Percentage of Participants Who Discontinued Study Drug Due to an AE | 0.0 Percentage of Participants |
| Part 1: Placebo | Percentage of Participants Who Discontinued Study Drug Due to an AE | 0.0 Percentage of Participants |
| Part 2: MK-5475 380 μg | Percentage of Participants Who Discontinued Study Drug Due to an AE | 0.0 Percentage of Participants |
| Part 2: Placebo | Percentage of Participants Who Discontinued Study Drug Due to an AE | 0.0 Percentage of Participants |
Primary
Percentage of Participants Who Experienced at Least 1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was assessed.
Time frame: Up to approximately 139 days
Population: All participants who received ≥1 dose of investigational treatment were analyzed according to treatment received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1: MK-5475 360 μg | Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) | 33.3 Percentage of Participants |
| Part 1: Placebo | Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) | 33.3 Percentage of Participants |
| Part 2: MK-5475 380 μg | Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) | 33.3 Percentage of Participants |
| Part 2: Placebo | Percentage of Participants Who Experienced at Least 1 Adverse Event (AE) | 80.0 Percentage of Participants |
Secondary
AUC0-24 Accumulation Ratio of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose to determine the AUC0-24 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-24 to the Day 1 AUC0-24.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of AUC0-24 accumulation ratio. Per protocol, AUC0-24 accumulation ratio was calculated for the participants who had concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | AUC0-24 Accumulation Ratio of MK-5475: Part 1 | 1.27 Ratio | Geometric Coefficient of Variation 30.1 |
Secondary
AUC0-24 of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose on Day 28 to determine the AUC0-24 of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation. AUC0-24 was calculated using extrapolated concentration at 24 hours postdose.
Time frame: Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of AUC0-24. Per protocol, AUC0-24 was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | AUC0-24 of MK-5475: Part 2 | Day 1 | NA hr*nM | — |
| Part 1: MK-5475 360 μg | AUC0-24 of MK-5475: Part 2 | Day 28 | 1.97 hr*nM | Geometric Coefficient of Variation 105.7 |
Secondary
AUC0-3 Accumulation Ratio of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose on to determine the AUC0-3 accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-3 to the Day 1 AUC0-3.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants who received at least 1 treatment and who contributed blood samples for analysis of accumulation. Per protocol, accumulation was calculated for the participants who had concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | AUC0-3 Accumulation Ratio of MK-5475: Part 2 | 1.11 Ratio | Geometric Coefficient of Variation 53.8 |
Secondary
AUC0-inf Accumulation Ratio of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose on Days 1-7 to determine the AUC0-inf accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 AUC0-inf to the Day 1 AUC0-inf.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of AUC0-inf accumulation ratio. Per protocol, AUC0-inf accumulation ratio was calculated for the participants who had concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | AUC0-inf Accumulation Ratio of MK-5475: Part 1 | 1.21 Ratio | Geometric Coefficient of Variation 31.1 |
Secondary
AUC0-inf of MK-5475: Part 2
Blood samples were taken pre-dose and at specified times post-dose to determine the AUC0-inf of MK-5475. Concentrations for samples collected pre-RHC in a time window of 6-8 hours postdose on Day 28 were used to derive PK parameter values on Day 28. A nominal elapsed time of 6.01 hours postdose was used in the calculation.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of AUC0-inf. Per protocol, AUC0-inf was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | AUC0-inf of MK-5475: Part 2 | Day 1 | NA hr*nM | — |
| Part 1: MK-5475 360 μg | AUC0-inf of MK-5475: Part 2 | Day 28 | 1.98 hr*nM | Geometric Coefficient of Variation 105.9 |
Secondary
Cmax Accumulation Ratio of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of Cmax accumulation ratio. Per protocol, Cmax accumulation ratio was calculated for the participants who had concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Cmax Accumulation Ratio of MK-5475: Part 1 | 1.17 Ratio | Geometric Coefficient of Variation 28.8 |
Secondary
Cmax Accumulation Ratio of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the Cmax accumulation ratio of MK-5475. Cmax accumulation ratio is the ratio of the Day 7 Cmax to the Day 1 Cmax.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 15: 1 hour postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of Cmax accumulation ratio. Per protocol, Cmax accumulation ratio was calculated for the participants who had concentration values.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Cmax Accumulation Ratio of MK-5475: Part 2 | 1.14 Ratio | Geometric Coefficient of Variation 51.6 |
Secondary
Cmax of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the Cmax of MK-5475.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of Cmax. Per protocol, Cmax was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | Cmax of MK-5475: Part 2 | Day 1 | 0.348 nM | Geometric Coefficient of Variation 48.4 |
| Part 1: MK-5475 360 μg | Cmax of MK-5475: Part 2 | Day 28 | 0.397 nM | Geometric Coefficient of Variation 71.4 |
Secondary
Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1
Plasma concentration of MK-5475 was quantified for each arm to determine Cmax.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of Cmax. Per protocol, Cmax was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1 | Day 1 | 0.830 nM | Geometric Coefficient of Variation 50.8 |
| Part 1: MK-5475 360 μg | Maximum Observed Plasma Concentration (Cmax) of MK-5475: Part 1 | Day 7 | 0.970 nM | Geometric Coefficient of Variation 59.1 |
Secondary
Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2
Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during part 1 and part 3.
Time frame: Baseline (between Day -5 and Day -1) and Day 28
Population: All Part 2 participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model, and who had available data at baseline and Day 28.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2 | -0.3 Percentage Change | Standard Deviation 4.7 |
| Part 1: Placebo | Percent Change From Baseline in Pulmonary Blood Volume (PBV) at Day 28: Part 2 | -2.8 Percentage Change | Standard Deviation 10.6 |
Secondary
Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1
Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of t½. Per protocol, t½ was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1 | Day 1 | 2.13 Hours | Geometric Coefficient of Variation 18.5 |
| Part 1: MK-5475 360 μg | Plasma Apparent Terminal Half-Life (t½) of MK-5475: Part 1 | Day 7 | 2.81 Hours | Geometric Coefficient of Variation 48.4 |
Secondary
Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose on Day 7 to determine the AUC0-24 of MK-5475. AUC0-24 values for Day 1 correspond to extrapolated values since collection on Day 1 stopped at 8 hours.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of AUC0-24. Per protocol, AUC0-24 was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1 | Day 1 | 3.31 hr*nM | Geometric Coefficient of Variation 68.7 |
| Part 1: MK-5475 360 μg | Plasma Area Under the Concentration Time-Curve From 0 to 24 Hours (AUC0-24) of MK-5475: Part 1 | Day 7 | 4.22 hr*nM | Geometric Coefficient of Variation 83.5 |
Secondary
Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1
Blood samples were taken predose and at specified times postdose to determine the AUC0-inf of MK-5475. Plasma AUC0-inf was defined as the area under the concentration vs. time curve for MK-5475 from 0 to infinite hours.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of AUC0-inf. Per protocol, AUC0-inf was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1 | Day 7 | 4.03 hr*nM | Geometric Coefficient of Variation 90.2 |
| Part 1: MK-5475 360 μg | Plasma Area Under the Concentration Time-Curve From 0 to Infinity (AUC0-inf) of MK-5475: Part 1 | Day 1 | 3.32 hr*nM | Geometric Coefficient of Variation 68.9 |
Secondary
Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1
Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Standard Deviation. Concentration values below the lower limit of quantification were treated as having a value of 0.
Time frame: 24 hours postdose on Day 7
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of C24. Per protocol, C24 was calculated for the participants who had concentration.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 1 | 0.02 nM | Standard Deviation 0.3 |
Secondary
Plasma Concentration 24 Hours Postdose (C24) of MK-5475: Part 2
Blood samples were taken to determine the C24 of MK-5475. Data are reported as Mean with Coefficient of Variation, but due to data entry limitations the table below labels them as Geometric Mean and Geometric Coefficient of Variation. Concentration values below the lower limit of quantification were treated as having a value of 0.
Time frame: 24 hours postdose on Day 7
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of C24. Per protocol, 24 hours samples were not collected. Therefore, no participants were analyzed.
Secondary
t½ of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the t½ of MK-5475.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of t½. Per protocol, t½ was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Part 1: MK-5475 360 μg | t½ of MK-5475: Part 2 | Day 1 | NA Hours | — |
| Part 1: MK-5475 360 μg | t½ of MK-5475: Part 2 | Day 28 | 2.06 Hours | Geometric Coefficient of Variation 62.4 |
Secondary
Time to Maximum Concentration (Tmax) of MK-5475: Part 1
Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475.
Time frame: Day 1: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4 and 8 hours postdose, Day 7: Predose, 5 minutes, 15 minutes, 0.5, 1, 2, 3, 4, 8 and 24 hours postdose
Population: The analysis population consisted of all participants in part 1 who received at least one dose of MK-5475 360 μg and who contributed blood samples for analysis of Tmax. Per protocol, Tmax was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Time to Maximum Concentration (Tmax) of MK-5475: Part 1 | Day 1 | 1.00 Hours |
| Part 1: MK-5475 360 μg | Time to Maximum Concentration (Tmax) of MK-5475: Part 1 | Day 7 | 1.00 Hours |
Secondary
Tmax of MK-5475: Part 2
Blood samples were taken predose and at specified times postdose to determine the Tmax of MK-5475.
Time frame: Day 1: Predose, 0.5, 1, 2 and 3 hours postdose, Day 28: Predose, 0.5, 1, 2 and 3 hours postdose
Population: The analysis population consisted of all participants in part 2 who received at least one dose of MK-5475 380 μg and who contributed blood samples for analysis of Tmax. Per protocol, Tmax was calculated for the participants who had concentration values.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Part 1: MK-5475 360 μg | Tmax of MK-5475: Part 2 | Day 1 | 1.50 Hours |
| Part 1: MK-5475 360 μg | Tmax of MK-5475: Part 2 | Day 28 | 1.50 Hours |